|Study Description:||The goal of this Phase 1 clinical research study is to learn the highest |
tolerable dose of the combination of the drugs BKM120 and olaparib that can be
given to patients with recurrent breast or ovarian cancer. The safety of these
drugs will also be studied.
BKM120 and olaparib are both designed to block the growth and division of
cancer cells, which may cause the cells to die.